Iovance Sinks Another 11% as Baird Cuts Target to $9 After Lung Cancer Data
Iovance Biotherapeutics (IOVA) fell 11% after Baird cut its price target to $9 from $11, following a 35% drop due to lung cancer trial data. The trial's 24.6% response rate matched earlier results, but a higher 59.1% rate in a post-hoc subgroup requires further study. Amtagvi's sales and Q3 results on Nov. 5 are now key focuses for investors.
How this was made
The 30-second read
Why it matters
The analyst downgrade and price drop reflect market disappointment in the trial's limited progress, reinforcing a bearish short‑term outlook.
Market read
The news directly moves IOVA shares and may influence peer biotech stocks with similar trial pipelines.
What to watch
Amtagvi melanoma sales remain strong and could cushion earnings despite lung‑cancer setbacks.
Background
Iovance Biotherapeutics (IOVA) reported Phase 2 lung‑cancer data that matched earlier response rates, prompting a Baird target cut and a sharp share decline.
Ticker impact
Baird cut IOVA's price target to $9 and the stock fell another 11% after weak lung‑cancer trial data.
likely further downside as investors price in the weaker trial readout and lower target.
Target cut is a fresh analyst action; the trial data did not improve, and the stock already slid 35% earlier.
Market effects
Biotech sector may see broader risk‑off as other companies with early‑stage oncology data face scrutiny.
US biotech indices could dip modestly in early trade.
Limited to investors tracking oncology pipelines; no major macro effect.
Counterpoint
If the upcoming OPTILISM trial shows stronger signals, the stock could rebound on a longer‑term upside.
Key entities
- CompanyIovance Biotherapeutics
NASDAQ‑listed biotech developing lifileucel.
- AnalystBaird
Equity research firm that lowered IOVA's price target.
